SAN FRANCISCO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 48,000 shares of the Company's common stock to one new employee (the "Inducement Grant") on December 13, 2024 (the "Grant Date"). The Inducement Grant has been granted pursuant to the Company's 2023 Inducement Plan (the "Plan"). The Inducement Grant was granted as an inducement material to the individual entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).
The Inducement Grant has an exercise price per share that is equal to the closing price of 89bio's common stock on the Grant Date. The Inducement Grant will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the employee's start date, and thereafter the remainder of the shares vest in 12 equal quarterly installments, subject to the employee's continued employment with 89bio through the applicable vesting dates.
kAmp3@FE gh3:@k^Am kAmgh3:@ :D 2 4=:?:42=\DE286 3:@A92C>246FE:42= 4@>A2?J 565:42E65 E@ E96 56G6=@A>6?E @7 36DE\:?\4=2DD E96C2A:6D 7@C A2E:6?ED H:E9 =:G6C 2?5 42C5:@>6E23@=:4 5:D62D6D H9@ =24< @AE:>2= EC62E>6?E @AE:@?D] %96 4@>A2?J :D 7@4FD65 @? C2A:5=J 25G2?4:?8 :ED =625 42?5:52E6[ A68@K276C>:?[ E9C@F89 !92D6 b 4=:?:42= 56G6=@A>6?E 7@C E96 EC62E>6?E @7 >6E23@=:4 5JD7F?4E:@?\2DD@4:2E65 DE62E@96A2E:E:D W|p$wX 2?5 D6G6C6 9JA6CEC:8=J46C:56>:2 W$w%vX] !68@K276C>:? :D 2 DA64:7:42==J 6?8:?66C65[ A@E6?E:2==J 36DE\:?\4=2DD 7:3C@3=2DE 8C@HE9 724E@C a' Wuvua'X 2?2=@8 H:E9 F?:BF6 8=J4@!tvJ=2E65 E649?@=@8J E92E @AE:>:K6D 3:@=@8:42= 24E:G:EJ E9C@F89 2? 6IE6?565 92=7\=:76] %96 4@>A2?J :D 9625BF2CE6C65 :? $2? uC2?4:D4@] u@C >@C6 :?7@C>2E:@?[ G:D:E k2 9C67lQ9EEADi^^HHH]8=@36?6HDH:C6]4@>^%C24<6Cn52E2l>'KJ!C0I~za);fK9*C:GB)J0"@g96<#?K<?b8(*I'Az(6pq2475E6|'a5Ip>bF|7CHc%:2HtF;:h:"h~wHe>upllQ C6=lQ?@7@==@HQmHHH]gh3:@]4@>k^2m @C 7@==@H E96 4@>A2?J @? k2 9C67lQ9EEADi^^HHH]8=@36?6HDH:C6]4@>^%C24<6Cn52E2l&p}22_>yt~KAs2Ar;=z{4ueyC:@rD&H"<eCf~w:)J;F@0(EB2eqcruGf9hHh_qs';7zaBdtr@)0\gv"#:CG5~e$f_Hh"D:xEtBuxc';z;v'HtK=CDfe"I&v7:5q(&fc=hJ'g0rrqH5y%0';z)!#"GdB_2qG4~?:u:zgh06yc;G&"%q*=9fyA{(gpA>'c9sFc_3'9fHyf<}{!HeI<aEr02yb;!9vd}''us5q*H2IGt=B&{z%z@x@Bg~"+rchuyF$ay'"euv{!8f7{d_f_dJ\4z%*qIt7C~JEA?K'5yy~H~Az}9%!7|#K;cy"$|G:'q;?vB=fKJ%7yqz}~$A'deqpFeBf7bh43wg574K2v$+{;G'8Ags3E7BrgeHEt0{e9~#eE@~#d};}"aw79a&%:z"fCE'3|ax%F%=A|H??+*F796xCwf=I7{0dxt4vF={:sf'??Q C6=lQ?@7@==@HQm{:?<65x?k^2m]k^AmkAmx?G6DE@C r@?E24Eik^AmkAmp??:6 r92?8k^AmkAmgh3:@[ x?4]k^AmkAmk2 9C67lQ>2:=E@i:?G6DE@CDogh3:@]4@>Qm:?G6DE@CDogh3:@]4@>k^2mk^AmkAm!y z6==696Ck^Am kAm{:76$4: p5G:D@CD[ {{rk^AmkAmZ'\e'f\cb_\fdfhk^AmkAmk2 9C67lQ>2:=E@iA<6==696Co=:76D4:25G:D@CD]4@>QmA<6==696Co=:76D4:25G:D@CD]4@>k^2mk^AmkAm|65:2 r@?E24Eik^AmkAm$96CJ= $62AJk^AmkAm#62= r96>:DECJk^AmkAmk2 9C67lQ>2:=E@iDD62AJoC62=496>:DECJ]4@>QmDD62AJoC62=496>:DECJ]4@>k^2mk^AmkAmk^AmkAmk^Am